Tevogen Bio, a clinical-stage biotechnology company based in Warren, on Monday announced a significant top-line revenue forecast for its oncology pipeline, projecting $1 billion in its launch year. The company said it also anticipates a cumulative revenue of $10 billion to $14 billion over the next five years.
This optimistic forecast is attributed to Tevogen’s “faster and cost-efficient drug development model,” which it believes could become a new standard for sustainable medical innovation.
The company’s unique approach focuses on creating off-the-shelf, genetically unmodified T cell therapies to treat infectious diseases and cancers.
Sadiq Khan, Tevogen’s chief commercial officer, highlighted the company’s commitment to patient well-being, particularly for vulnerable cancer patients. Khan noted that the company’s first pivotal study for its product TVGN 489 is being designed to specifically help patients undergoing immunosuppressive treatments and chemotherapy to combat SARS-CoV-2 (COVID-19) infection.
“At Tevogen, we strive to turn our vision into reality ensuring our commitment translates into tangible results. Our priority is the well-being of cancer patients. With compelling evidence that SARS-CoV-2 remains a serious threat to those undergoing immunosuppressive treatments and chemotherapy, our first pivotal study with TVGN 489 is being designed specifically to help these vulnerable patients combat the infection,” Khan said.
The revenue projections are considered forward-looking statements and are subject to the risks and uncertainties associated with the drug development process, including clinical trial outcomes and regulatory approval.
